ID   CATF_HUMAN              Reviewed;         484 AA.
AC   Q9UBX1; B2R964; O95240; Q9NSU4; Q9UKQ5;
DT   24-JAN-2001, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-2000, sequence version 1.
DT   07-APR-2021, entry version 179.
DE   RecName: Full=Cathepsin F;
DE            Short=CATSF;
DE            EC=3.4.22.41;
DE   Flags: Precursor;
GN   Name=CTSF;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Prostate;
RX   PubMed=10318784; DOI=10.1074/jbc.274.20.13800;
RA   Santamaria I., Velasco G., Pendas A.M., Paz A., Lopez-Otin C.;
RT   "Molecular cloning and structural and functional characterization of human
RT   cathepsin F, a new cysteine proteinase of the papain family with a long
RT   propeptide domain.";
RL   J. Biol. Chem. 274:13800-13809(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Ovary;
RX   PubMed=10198209; DOI=10.1006/bbrc.1999.0461;
RA   Naegler D.K., Sulea T., Menard R.;
RT   "Full-length cDNA of human cathepsin F predicts the presence of a cystatin
RT   domain at the N-terminus of the cysteine protease zymogen.";
RL   Biochem. Biophys. Res. Commun. 257:313-318(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=10661872; DOI=10.1515/bc.1999.185;
RA   Wex T., Wex H., Broemme D.;
RT   "The human cathepsin F gene -- a fusion product between an ancestral
RT   cathepsin and cystatin gene.";
RL   Biol. Chem. 380:1439-1442(1999).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=10362521; DOI=10.1006/bbrc.1999.0700;
RA   Wex T., Levy B., Wex H., Bromme D.;
RT   "Human cathepsins F and W: a new subgroup of cathepsins.";
RL   Biochem. Biophys. Res. Commun. 259:401-407(1999).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Kidney;
RA   Deussing J., Tisljar K., Papazoglou A., Peters C.;
RT   "Cathepsin F, a novel cysteine protease with an extremely long
RT   propeptide.";
RL   Submitted (MAR-1999) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Lung, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 147-484, AND CHARACTERIZATION.
RC   TISSUE=Brain, and Smooth muscle;
RX   PubMed=9822672; DOI=10.1074/jbc.273.48.32000;
RA   Wang B., Shi G.-P., Yao P.M., Li Z., Chapman H.A., Broemme D.;
RT   "Human cathepsin F. Molecular cloning, functional expression, tissue
RT   localization, and enzymatic characterization.";
RL   J. Biol. Chem. 273:32000-32008(1998).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 161-484.
RC   TISSUE=Testis;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [10]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-367; ASN-378 AND ASN-440.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of multiple
RT   enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 271-484, ACTIVE SITE, AND
RP   DISULFIDE BONDS.
RX   PubMed=12225749; DOI=10.1016/s0022-2836(02)00780-5;
RA   Somoza J.R., Palmer J.T., Ho J.D.;
RT   "The crystal structure of human cathepsin F and its implications for the
RT   development of novel immunomodulators.";
RL   J. Mol. Biol. 322:559-568(2002).
RN   [12]
RP   VARIANTS CLN13 CYS-231; ARG-321; ALA-458 AND LEU-480.
RX   PubMed=23297359; DOI=10.1093/hmg/dds558;
RA   Smith K.R., Dahl H.H., Canafoglia L., Andermann E., Damiano J., Morbin M.,
RA   Bruni A.C., Giaccone G., Cossette P., Saftig P., Groetzinger J.,
RA   Schwake M., Andermann F., Staropoli J.F., Sims K.B., Mole S.E.,
RA   Franceschetti S., Alexander N.A., Cooper J.D., Chapman H.A., Carpenter S.,
RA   Berkovic S.F., Bahlo M.;
RT   "Cathepsin F mutations cause Type B Kufs disease, an adult-onset neuronal
RT   ceroid lipofuscinosis.";
RL   Hum. Mol. Genet. 22:1417-1423(2013).
CC   -!- FUNCTION: Thiol protease which is believed to participate in
CC       intracellular degradation and turnover of proteins. Has also been
CC       implicated in tumor invasion and metastasis.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=The recombinant enzyme cleaves synthetic substrates with Phe
CC         and Leu (better than Val) in P2, with high specificity constant
CC         (k(cat)/K(m)) comparable to that of cathepsin L.; EC=3.4.22.41;
CC   -!- SUBCELLULAR LOCATION: Lysosome.
CC   -!- TISSUE SPECIFICITY: High expression levels in heart, skeletal muscle,
CC       brain, testis and ovary; moderate levels in prostate, placenta, liver
CC       and colon; and no detectable expression in peripheral leukocytes and
CC       thymus.
CC   -!- DISEASE: Ceroid lipofuscinosis, neuronal, 13 (CLN13) [MIM:615362]: A
CC       form of neuronal ceroid lipofuscinosis characterized by adult onset of
CC       progressive cognitive decline and motor dysfunction leading to dementia
CC       and often early death. Some patients develop seizures. Neuronal ceroid
CC       lipofuscinoses are progressive neurodegenerative, lysosomal storage
CC       diseases characterized by intracellular accumulation of autofluorescent
CC       liposomal material. {ECO:0000269|PubMed:23297359}. Note=The disease is
CC       caused by variants affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the peptidase C1 family. {ECO:0000255|PROSITE-
CC       ProRule:PRU10088, ECO:0000255|PROSITE-ProRule:PRU10089}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AJ007331; CAB42883.1; -; mRNA.
DR   EMBL; AF088886; AAD26616.2; -; mRNA.
DR   EMBL; AF132894; AAD41790.1; -; Genomic_DNA.
DR   EMBL; AF136279; AAF13146.1; -; mRNA.
DR   EMBL; AF071748; AAC78838.1; -; mRNA.
DR   EMBL; AF071749; AAC78839.1; -; mRNA.
DR   EMBL; AK313657; BAG36411.1; -; mRNA.
DR   EMBL; BC011682; AAH11682.1; -; mRNA.
DR   EMBL; BC036451; AAH36451.1; -; mRNA.
DR   EMBL; AL137742; CAB70900.1; -; mRNA.
DR   CCDS; CCDS8144.1; -.
DR   RefSeq; NP_003784.2; NM_003793.3.
DR   PDB; 1D5U; Model; -; A=271-484.
DR   PDB; 1M6D; X-ray; 1.70 A; A/B=271-484.
DR   PDBsum; 1D5U; -.
DR   PDBsum; 1M6D; -.
DR   SMR; Q9UBX1; -.
DR   BioGRID; 114261; 20.
DR   IntAct; Q9UBX1; 8.
DR   STRING; 9606.ENSP00000310832; -.
DR   BindingDB; Q9UBX1; -.
DR   ChEMBL; CHEMBL2517; -.
DR   DrugBank; DB02243; 4-Morpholin-4-Yl-Piperidine-1-Carboxylic Acid [1-(3-Benzenesulfonyl-1-Propyl-Allylcarbamoyl)-2-Phenylethyl]-Amide.
DR   DrugBank; DB01871; [1-(1-Benzyl-3-Hydroxy-2-Oxo-Propylcarbamoyl)-2-Phenyl-Ethyl]-Carbamic Acid Benzyl Ester.
DR   DrugBank; DB01810; [1-(1-Methyl-4,5-Dioxo-Pent-2-Enylcarbamoyl)-2-Phenyl-Ethyl]-Carbamic Acid Benzyl Ester.
DR   DrugBank; DB08775; Benzoyl-tyrosine-alanine-fluoro-methyl ketone.
DR   DrugBank; DB03536; Benzyl N-[(2S)-5-(diaminomethylamino)-1-[[(2S)-4-fluoro-3-oxobutan-2-yl]amino]-1-oxopentan-2-yl]carbamate.
DR   DrugBank; DB07913; HOMOPHENYLALANINYLMETHANE.
DR   DrugBank; DB03691; WRR-112.
DR   DrugBank; DB03573; WRR-99.
DR   DrugCentral; Q9UBX1; -.
DR   GuidetoPHARMACOLOGY; 2347; -.
DR   MEROPS; C01.018; -.
DR   GlyConnect; 1080; 4 N-Linked glycans (2 sites).
DR   GlyGen; Q9UBX1; 5 sites.
DR   iPTMnet; Q9UBX1; -.
DR   PhosphoSitePlus; Q9UBX1; -.
DR   BioMuta; CTSF; -.
DR   DMDM; 12643325; -.
DR   EPD; Q9UBX1; -.
DR   jPOST; Q9UBX1; -.
DR   MassIVE; Q9UBX1; -.
DR   MaxQB; Q9UBX1; -.
DR   PaxDb; Q9UBX1; -.
DR   PeptideAtlas; Q9UBX1; -.
DR   PRIDE; Q9UBX1; -.
DR   ProteomicsDB; 84089; -.
DR   Antibodypedia; 30202; 279 antibodies.
DR   DNASU; 8722; -.
DR   Ensembl; ENST00000310325; ENSP00000310832; ENSG00000174080.
DR   GeneID; 8722; -.
DR   KEGG; hsa:8722; -.
DR   UCSC; uc001oip.4; human.
DR   CTD; 8722; -.
DR   DisGeNET; 8722; -.
DR   GeneCards; CTSF; -.
DR   HGNC; HGNC:2531; CTSF.
DR   HPA; ENSG00000174080; Low tissue specificity.
DR   MalaCards; CTSF; -.
DR   MIM; 603539; gene.
DR   MIM; 615362; phenotype.
DR   neXtProt; NX_Q9UBX1; -.
DR   OpenTargets; ENSG00000174080; -.
DR   Orphanet; 352709; CLN13 disease.
DR   PharmGKB; PA27031; -.
DR   VEuPathDB; HostDB:ENSG00000174080.10; -.
DR   eggNOG; KOG1542; Eukaryota.
DR   GeneTree; ENSGT00940000162141; -.
DR   HOGENOM; CLU_012184_10_0_1; -.
DR   InParanoid; Q9UBX1; -.
DR   OMA; RGHMQAC; -.
DR   OrthoDB; 1264766at2759; -.
DR   PhylomeDB; Q9UBX1; -.
DR   TreeFam; TF314550; -.
DR   BRENDA; 3.4.22.41; 2681.
DR   PathwayCommons; Q9UBX1; -.
DR   Reactome; R-HSA-2132295; MHC class II antigen presentation.
DR   BioGRID-ORCS; 8722; 21 hits in 995 CRISPR screens.
DR   ChiTaRS; CTSF; human.
DR   EvolutionaryTrace; Q9UBX1; -.
DR   GeneWiki; Cathepsin_F; -.
DR   GenomeRNAi; 8722; -.
DR   Pharos; Q9UBX1; Tchem.
DR   PRO; PR:Q9UBX1; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   RNAct; Q9UBX1; protein.
DR   Bgee; ENSG00000174080; Expressed in right hemisphere of cerebellum and 247 other tissues.
DR   ExpressionAtlas; Q9UBX1; baseline and differential.
DR   Genevisible; Q9UBX1; HS.
DR   GO; GO:0062023; C:collagen-containing extracellular matrix; HDA:BHF-UCL.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; IBA:GO_Central.
DR   GO; GO:1903561; C:extracellular vesicle; HDA:UniProtKB.
DR   GO; GO:0043202; C:lysosomal lumen; TAS:Reactome.
DR   GO; GO:0005764; C:lysosome; IBA:GO_Central.
DR   GO; GO:0004197; F:cysteine-type endopeptidase activity; IBA:GO_Central.
DR   GO; GO:0019886; P:antigen processing and presentation of exogenous peptide antigen via MHC class II; TAS:Reactome.
DR   GO; GO:0006508; P:proteolysis; TAS:ProtInc.
DR   GO; GO:0051603; P:proteolysis involved in cellular protein catabolic process; IBA:GO_Central.
DR   CDD; cd02248; Peptidase_C1A; 1.
DR   InterPro; IPR038765; Papain-like_cys_pep_sf.
DR   InterPro; IPR000169; Pept_cys_AS.
DR   InterPro; IPR025660; Pept_his_AS.
DR   InterPro; IPR000668; Peptidase_C1A_C.
DR   InterPro; IPR039417; Peptidase_C1A_papain-like.
DR   InterPro; IPR013201; Prot_inhib_I29.
DR   Pfam; PF08246; Inhibitor_I29; 1.
DR   Pfam; PF00112; Peptidase_C1; 1.
DR   PRINTS; PR00705; PAPAIN.
DR   SMART; SM00848; Inhibitor_I29; 1.
DR   SMART; SM00645; Pept_C1; 1.
DR   SUPFAM; SSF54001; SSF54001; 1.
DR   PROSITE; PS00139; THIOL_PROTEASE_CYS; 1.
DR   PROSITE; PS00639; THIOL_PROTEASE_HIS; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Disease variant; Disulfide bond; Glycoprotein; Hydrolase;
KW   Lysosome; Neurodegeneration; Neuronal ceroid lipofuscinosis; Protease;
KW   Reference proteome; Signal; Thiol protease; Zymogen.
FT   SIGNAL          1..19
FT                   /evidence="ECO:0000255"
FT   PROPEP          20..270
FT                   /note="Activation peptide"
FT                   /id="PRO_0000026202"
FT   CHAIN           271..484
FT                   /note="Cathepsin F"
FT                   /id="PRO_0000026203"
FT   ACT_SITE        295
FT                   /evidence="ECO:0000269|PubMed:12225749"
FT   ACT_SITE        431
FT                   /evidence="ECO:0000269|PubMed:12225749"
FT   ACT_SITE        451
FT                   /evidence="ECO:0000250"
FT   CARBOHYD        160
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        195
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        367
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:19159218"
FT   CARBOHYD        378
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:19159218"
FT   CARBOHYD        440
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:19159218"
FT   DISULFID        292..333
FT                   /evidence="ECO:0000269|PubMed:12225749"
FT   DISULFID        326..366
FT                   /evidence="ECO:0000269|PubMed:12225749"
FT   DISULFID        424..472
FT                   /evidence="ECO:0000250"
FT   VARIANT         153
FT                   /note="Q -> R (in dbSNP:rs11550508)"
FT                   /id="VAR_051513"
FT   VARIANT         231
FT                   /note="Y -> C (in CLN13; dbSNP:rs143889283)"
FT                   /evidence="ECO:0000269|PubMed:23297359"
FT                   /id="VAR_070159"
FT   VARIANT         321
FT                   /note="Q -> R (in CLN13; dbSNP:rs397514731)"
FT                   /evidence="ECO:0000269|PubMed:23297359"
FT                   /id="VAR_070160"
FT   VARIANT         458
FT                   /note="G -> A (in CLN13; dbSNP:rs397514732)"
FT                   /evidence="ECO:0000269|PubMed:23297359"
FT                   /id="VAR_070161"
FT   VARIANT         480
FT                   /note="S -> L (in CLN13; dbSNP:rs397514733)"
FT                   /evidence="ECO:0000269|PubMed:23297359"
FT                   /id="VAR_070162"
FT   CONFLICT        305
FT                   /note="E -> K (in Ref. 5; AAF13146)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        442..484
FT                   /note="SDVPFWAIKNSWGTDWGEKGYYYLHRGSGACGVNTMASSAVVD -> EFRCL
FT                   SCIQPGHRQGWDHSISGPLEGK (in Ref. 9)"
FT                   /evidence="ECO:0000305"
FT   HELIX           277..280
FT                   /evidence="ECO:0007744|PDB:1M6D"
FT   STRAND          291..293
FT                   /evidence="ECO:0007744|PDB:1M6D"
FT   HELIX           295..312
FT                   /evidence="ECO:0007744|PDB:1M6D"
FT   HELIX           320..326
FT                   /evidence="ECO:0007744|PDB:1M6D"
FT   STRAND          328..330
FT                   /evidence="ECO:0007744|PDB:1M6D"
FT   HELIX           338..348
FT                   /evidence="ECO:0007744|PDB:1M6D"
FT   TURN            354..356
FT                   /evidence="ECO:0007744|PDB:1M6D"
FT   HELIX           370..372
FT                   /evidence="ECO:0007744|PDB:1M6D"
FT   STRAND          378..382
FT                   /evidence="ECO:0007744|PDB:1M6D"
FT   HELIX           387..397
FT                   /evidence="ECO:0007744|PDB:1M6D"
FT   STRAND          400..404
FT                   /evidence="ECO:0007744|PDB:1M6D"
FT   HELIX           407..411
FT                   /evidence="ECO:0007744|PDB:1M6D"
FT   STRAND          414..417
FT                   /evidence="ECO:0007744|PDB:1M6D"
FT   HELIX           421..423
FT                   /evidence="ECO:0007744|PDB:1M6D"
FT   STRAND          431..441
FT                   /evidence="ECO:0007744|PDB:1M6D"
FT   STRAND          444..450
FT                   /evidence="ECO:0007744|PDB:1M6D"
FT   STRAND          462..469
FT                   /evidence="ECO:0007744|PDB:1M6D"
FT   HELIX           471..473
FT                   /evidence="ECO:0007744|PDB:1M6D"
FT   TURN            474..477
FT                   /evidence="ECO:0007744|PDB:1M6D"
FT   STRAND          479..482
FT                   /evidence="ECO:0007744|PDB:1M6D"
SQ   SEQUENCE   484 AA;  53366 MW;  1D5D551B489D822B CRC64;
     MAPWLQLLSL LGLLPGAVAA PAQPRAASFQ AWGPPSPELL APTRFALEMF NRGRAAGTRA
     VLGLVRGRVR RAGQGSLYSL EATLEEPPCN DPMVCRLPVS KKTLLCSFQV LDELGRHVLL
     RKDCGPVDTK VPGAGEPKSA FTQGSAMISS LSQNHPDNRN ETFSSVISLL NEDPLSQDLP
     VKMASIFKNF VITYNRTYES KEEARWRLSV FVNNMVRAQK IQALDRGTAQ YGVTKFSDLT
     EEEFRTIYLN TLLRKEPGNK MKQAKSVGDL APPEWDWRSK GAVTKVKDQG MCGSCWAFSV
     TGNVEGQWFL NQGTLLSLSE QELLDCDKMD KACMGGLPSN AYSAIKNLGG LETEDDYSYQ
     GHMQSCNFSA EKAKVYINDS VELSQNEQKL AAWLAKRGPI SVAINAFGMQ FYRHGISRPL
     RPLCSPWLID HAVLLVGYGN RSDVPFWAIK NSWGTDWGEK GYYYLHRGSG ACGVNTMASS
     AVVD
//
